EP1986674A4 - Methionine-containing protein or peptide compositions and methods of making and using - Google Patents

Methionine-containing protein or peptide compositions and methods of making and using

Info

Publication number
EP1986674A4
EP1986674A4 EP07750726A EP07750726A EP1986674A4 EP 1986674 A4 EP1986674 A4 EP 1986674A4 EP 07750726 A EP07750726 A EP 07750726A EP 07750726 A EP07750726 A EP 07750726A EP 1986674 A4 EP1986674 A4 EP 1986674A4
Authority
EP
European Patent Office
Prior art keywords
methionine
making
methods
containing protein
peptide compositions
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP07750726A
Other languages
German (de)
French (fr)
Other versions
EP1986674A2 (en
Inventor
Thomas E Tarara
Cynthia Stevenson
Stewart Thompson
Reinhard Vehring
Negar Sadrzadeh
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Nektar Therapeutics
Original Assignee
Nektar Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics
Publication of EP1986674A2 publication Critical patent/EP1986674A2/en
Publication of EP1986674A4 publication Critical patent/EP1986674A4/en
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/28—Insulins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/1841—Transforming growth factor [TGF]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18—Growth factors; Growth regulators
    • A61K38/185—Nerve growth factor [NGF]; Brain derived neurotrophic factor [BDNF]; Ciliary neurotrophic factor [CNTF]; Glial derived neurotrophic factor [GDNF]; Neurotrophins, e.g. NT-3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/29—Parathyroid hormone (parathormone); Parathyroid hormone-related peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/007—Pulmonary tract; Aromatherapy
    • A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
    • A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
EP07750726A 2006-02-13 2007-02-13 Methionine-containing protein or peptide compositions and methods of making and using Withdrawn EP1986674A4 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US77338406P 2006-02-13 2006-02-13
PCT/US2007/003905 WO2007095288A2 (en) 2006-02-13 2007-02-13 Methionine-containing protein or peptide compositions and methods of making and using

Publications (2)

Publication Number Publication Date
EP1986674A2 EP1986674A2 (en) 2008-11-05
EP1986674A4 true EP1986674A4 (en) 2009-11-11

Family

ID=38372110

Family Applications (1)

Application Number Title Priority Date Filing Date
EP07750726A Withdrawn EP1986674A4 (en) 2006-02-13 2007-02-13 Methionine-containing protein or peptide compositions and methods of making and using

Country Status (2)

Country Link
EP (1) EP1986674A4 (en)
WO (1) WO2007095288A2 (en)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070099831A1 (en) * 2005-09-06 2007-05-03 Paul Morley Parathyroid hormone analogues and methods of use
WO2008145323A1 (en) * 2007-05-31 2008-12-04 F. Hoffmann-La Roche Ag Pharmaceutical formulation for interferons
HUE030537T2 (en) 2008-01-09 2017-05-29 Sanofi Aventis Deutschland Novel insulin derivatives having an extremely delayed time-action profile
JP5364310B2 (en) * 2008-07-14 2013-12-11 アルフレッサファーマ株式会社 Method for stabilizing microparticles to which reactive substances are bound, and reagent containing the microparticles
NZ592283A (en) 2008-10-17 2012-09-28 Sanofi Aventis Deutschland Combination of an insulin and the GLP-1 agonist AVE0010
MX2012005184A (en) 2009-11-13 2012-06-08 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist and methionine.
MX2012005186A (en) 2009-11-13 2012-06-08 Sanofi Aventis Deutschland Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine.
FR2954325B1 (en) * 2009-12-23 2012-02-03 Flamel Tech Sa AMPHIPHILIC POLYMER FUNCTIONALIZED BY METHIONINE
EP2364690A1 (en) * 2010-02-12 2011-09-14 Centro De Ingenieria Genetica Y Biotecnologia Orally administrable pharmaceutical pellet of epidermal growth factor
JP6199186B2 (en) 2010-08-30 2017-09-20 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Use of AVE0010 for the manufacture of a medicament for the treatment of type 2 diabetes
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
US20140088014A1 (en) 2011-06-07 2014-03-27 Asahi Kasei Pharma Corporation Freeze-dried preparation containing high-purity pth and method for producing same
CA2879317C (en) * 2011-08-01 2019-01-15 Monash University Method and formulation for inhalation
SI2750699T1 (en) 2011-08-29 2015-11-30 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
TWI559929B (en) 2011-09-01 2016-12-01 Sanofi Aventis Deutschland Pharmaceutical composition for use in the treatment of a neurodegenerative disease
TWI780236B (en) 2013-02-04 2022-10-11 法商賽諾菲公司 Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
BR112015022484A2 (en) * 2013-03-13 2017-07-18 Genentech Inc reduced oxidation formulations
AR095398A1 (en) 2013-03-13 2015-10-14 Genentech Inc FORMULATIONS WITH REDUCED OXIDATION
CN114939156A (en) 2014-01-09 2022-08-26 赛诺菲 Stabilized pharmaceutical formulations of insulin aspart
EP3091995B1 (en) 2014-01-09 2024-03-20 Sanofi Stabilized pharmaceutical formulations of insulin aspart
US9895424B2 (en) 2014-01-09 2018-02-20 Sanofi Stabilized pharmaceutical formulations of insulin analogues and/or insulin derivatives
US10806770B2 (en) 2014-10-31 2020-10-20 Monash University Powder formulation
JP6970615B2 (en) 2014-12-12 2021-11-24 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Insulin glargine / lixisenatide fixed ratio prescription
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
WO1994007514A1 (en) * 1992-09-29 1994-04-14 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US6541450B1 (en) * 1994-06-20 2003-04-01 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2005000267A2 (en) * 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5358708A (en) * 1993-01-29 1994-10-25 Schering Corporation Stabilization of protein formulations
ES2254164T3 (en) * 1999-10-29 2006-06-16 Nektar Therapeutics DRY POWDER COMPOSITIONS WITH IMPROVED DISPERSABILITY.

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5272135A (en) * 1991-03-01 1993-12-21 Chiron Ophthalmics, Inc. Method for the stabilization of methionine-containing polypeptides
WO1994007514A1 (en) * 1992-09-29 1994-04-14 Inhale Therapeutic Systems Pulmonary delivery of active fragments of parathyroid hormone
US6541450B1 (en) * 1994-06-20 2003-04-01 National Research Council Of Canada Parathyroid hormone analogues for the treatment of osteoporosis
WO2005000267A2 (en) * 2003-05-28 2005-01-06 Nektar Therapeutics Spray drying of an alcoholic aqueous solution for the manufacture of a water-insoluble active agentmicroparticle with a partial or complete amino acid and/or phospholipid coat

Also Published As

Publication number Publication date
WO2007095288A2 (en) 2007-08-23
EP1986674A2 (en) 2008-11-05
WO2007095288A3 (en) 2008-07-03

Similar Documents

Publication Publication Date Title
EP1986674A4 (en) Methionine-containing protein or peptide compositions and methods of making and using
IL262205A (en) Protein formulations and methods of making same
HK1249115A1 (en) Peptide sequences and compositions
HK1216486A1 (en) Protein drink and method of making same
HK1122196A1 (en) Protein hydrolysates and method of making
EP2102355A4 (en) Long acting proteins and peptides and methods of making and using the same
IL209386A0 (en) Compositions containing, methods involving, and uses of non-natural amino acids and polypeptides
EP1987068A4 (en) Oligosaccharide modification and labeling of proteins
PL1940240T3 (en) Protein isolate compositions and uses thereof
IL190748A0 (en) Methods and compositions comprising non-natural amino acids
IL187617A0 (en) Lkktet and/or lkktnt peptide compositions and methods
IL197501A0 (en) Modifications of cupredoxin derived peptides and methods of use thereof
EP2029799A4 (en) Thermostable proteins and methods of making and using thereof
EP2109673A4 (en) Methods and compositions for enhanced protein expression and purification
EP2234636A4 (en) Stabilized formulations of peptides and proteins
PL1998790T3 (en) Compositions containing peptides with non-natural amino acids and methods of use
EP1789066A4 (en) Compositions and methods of using alpha-fetoprotein growth inhibitory peptides
PL2392587T3 (en) Peptide sequences and compositions
AU2006901628A0 (en) Site-selective derivatisation of peptides and proteins
GB0604920D0 (en) Peptide sequences and compositions
GB0614260D0 (en) Peptide sequences and compositions
GB0602416D0 (en) Peptide sequences and compositions

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080818

AK Designated contracting states

Kind code of ref document: A2

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RIN1 Information on inventor provided before grant (corrected)

Inventor name: TARARA, THOMAS, E.

Inventor name: STEVENSON, CYNTHIA

Inventor name: THOMPSON, STEWART

Inventor name: VEHRING, REINHARD

Inventor name: SADRZADEH, NEGAR

A4 Supplementary search report drawn up and despatched

Effective date: 20091014

17Q First examination report despatched

Effective date: 20100209

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20100820